Update on GPIIb/IIIa antagonists

Julien Hanson Natural and Synthetic Drugs Research Centre, Department of Medicinal Chemistry, , University of Liège, 1, av. de l’Hôpital, , B36 Sart-Tilman, B-4000 Liège, Belgium. [email protected]

Xavier de Leval Natural and Synthetic Drugs Research Centre, Department of Medicinal Chemistry, , University of Liège, 1, av. de l’Hôpital, , B36 Sart-Tilman, B-4000 Liège, Belgium. [email protected]

Philippe Kolh Natural and Synthetic Drugs Research Centre, Department of Medicinal Chemistry, , University of Liège, 1, av. de l’Hôpital, , B36 Sart-Tilman, B-4000 Liège, Belgium. [email protected]

Claudiu Supuran Natural and Synthetic Drugs Research Centre, Department of Medicinal Chemistry, , University of Liège, 1, av. de l’Hôpital, , B36 Sart-Tilman, B-4000 Liège, Belgium. [email protected]

Bernard Pirotte Natural and Synthetic Drugs Research Centre, Department of Medicinal Chemistry, , University of Liège, 1, av. de l’Hôpital, , B36 Sart-Tilman, B-4000 Liège, Belgium. [email protected]

Jean-Michel Dogné Natural and Synthetic Drugs Research Centre, Department of Medicinal Chemistry, , University of Liège, 1, av. de l’Hôpital, , B36 Sart-Tilman, B-4000 Liège, Belgium. [email protected]

Abstract

Since platelet aggregation is implicated in many pathological situations such as myocardial infarction, stroke, unstable angina and coronary artery disease, potent and safe antiplatelet agents would be useful for treating and preventing these diseases. Exposure of glycoprotein (GP)IIb/IIIa is the final common pathway leading to platelet activation and aggregate formation. Thus, the development of agents acting on this complex is an active area of research. Indeed, three GPIIb/IIIa antagonists are currently marketed but can only be intravenously administrated. Therefore, efforts are made to discover orally-active agents of this class, in order to use them for treatment of chronic disease or prevention of cardiovascular events. Although some clinical evaluation of orally-active compounds gave disappointing and discouraging results, research is still conducted to find compounds characterised by a better binding profile. This review describes 16 patents on new GPIIb/IIIa antagonists and more than 40 molecules characterised by strong activity against GPIIb/IIIa.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Update on GPIIb/IIIa antagonists

Information for

Open access

Opportunities

Help and information

Update on GPIIb/IIIa antagonists

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature